IPAK

Clinical Research Priorities

Priority #1.  Healthy Brains 2030.

With the Neurodevelopment Research Reform Consortium, we have determined that the highest priority clinical research is the safe and low-cost removal of aluminum from the brains of children via intranasal insulin and intranasal deferoxamine in comparison to ketogenic diet.

This research is to be conducted by extramural researchers.  Extensive literature exists on the effects of intranasal insulin and intranasal deferoxamine for iron removal (animal models) and intranasal deferoxamine, the effects on aluminum removal are supported.  Downstream hepatic and renal protection are a secondary important priorities.

To support this research, donate to the IPAK Clinical Research Prioritiesinitiative here.